Abstract: Method for simultaneously determining alleles present in a set of loci from at least one nucleic acid sample comprising the steps: a) providing said at least one sample, b) subjecting said sample to a nucleic acid amplification reaction using a primer pair simultaneously primer pairs specific and optimized for each of the loci of a set of at least three loci selected from the group consisting of D2S1360, D7S1517, D8S1132, D9S1118, D10S2325, D11S554, D12S1064, D12S391, D17S1290, D19S253, MYCLl, P450CYP19 and SE-33, and c) evaluating the length and optionally the relative quantity of amplification products obtained from step b) or from the analysis of one or two of the above loci to determine and/or optionally quantify the alleles present at each of the loci analyzed in the set within said sample.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV, V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.